Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3529-3529 ◽  
Author(s):  
R. Adam ◽  
M. Sebagh ◽  
M. Plasse ◽  
V. Karam ◽  
S. Giachetti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Hepatic Resection ◽  
Systemic Chemotherapy ◽  
Liver Histology ◽  
Colorectal Cancer Liver Metastases

scholarly journals Updates of colorectal cancer liver metastases therapy: review on DEBIRI

2020 ◽  
Vol 7 (1) ◽  
pp. HEP16 ◽  
Author(s):  
Giammaria Fiorentini ◽  
Donatella Sarti ◽  
Roberto Nani ◽  
Camillo Aliberti ◽  
Caterina Fiorentini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Tumor Response ◽  
Public Health Issue ◽  
Advanced Stage ◽  
Stage At Diagnosis ◽  
Colorectal Cancer Liver Metastases ◽  
Safety And Efficacy ◽  
Metastatic Sites

Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

scholarly journals Patterns of Lymph Node Recurrence in Colorectal Cancer Liver Metastases after Surgery: A Retrospective Longitudinal Study

2017 ◽  
Vol 6 (2) ◽  
pp. 35
Author(s):  
Tuck Leong Yong ◽  
Nezor Houli ◽  
Graham Starkey ◽  
Mehrdad Nikfarjam ◽  
Robert Jones ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Liver Resection ◽  
Liver Metastases ◽  
Hepatic Resection ◽  
Predictive Factor ◽  
Colorectal Cancer Liver Metastases ◽  
Lymph Node Recurrence ◽  
Post Surgery

Background: Hepatic resection is the standard treatment for resectable colorectal cancer liver metastases. There is evidence that lymphatics play a role in disease recurrence post-surgery. The aim of this retrospective study is to assess patterns of lymph node recurrence after liver resection. Methods: Patients who had liver resection for colorectal cancer metastasis between 1 January 2010 and 31 December 2015 at 2 institutions in Melbourne, Australia were included. Data was collected from databases located at the 2 surgical centres.Results: Seventy-four patients were included in the study. Follow-up period was for a mean of 31.4 months. Lymph node recurrence was seen in 39.2% of patients during follow-up. Initial recurrence sites after hepatectomy was mainly in visceral-site only. Lymph node recurrences became more prominent during subsequent Recurrence Stages (RS) (RS1 – 22.4%, RS2 – 50.0%, RS3 – 50.0%, RS4 – 71.4%, RS5 – 66.7%, and RS6 – 0%). No predictive factor showed statistically significant relation to development of nodal recurrence. Conclusion: Lymph node recurrences after hepatic resection for liver metastases usually occur subsequent to a visceral-site only metastasis. There is no predictive factor as to which nodal group would be involved due to the complexity of liver lymphatic drainage.

Sign in / Sign up

Export Citation Format

Share Document